

SAFETY DATA SHEET

1. Identification

Product identifier	PredniSONE Oral Solution USP, 5mg/5mL
Other means of identification	None.
Recommended use	Indicated for inflammation, severe allergies, complications of chronic illnesses, and other medical problems.
Recommended restrictions	None known.

Manufacturer/Importer/Supplier/Distributor information

Company name	West-Ward Pharmaceuticals Corporation
Address	1809 Wilson Road
	Columbus, Ohio 43228
Telephone	(614) 276-4000
Emergency phone number	(614) 276-4000

2. Hazard(s) identification

Physical hazards	Not classified.
Health hazards	Not classified.
OSHA defined hazards	Not classified.
Label elements	
Hazard symbol	None.
Signal word	Warning
Hazard statement	This is a pharmaceutical product designed to be prescribed by a licensed health care professional. Should any person while using this product observe any adverse health effects, they should seek medical treatment.
Precautionary statement	
Prevention	Observe good industrial hygiene practices.
Response	Wash hands after handling.
Storage	Store away from incompatible materials. Store at 25°C (77°F); excursions permitted to 15 - 30 °C (59 - 86 °F). Keep container tightly closed.
Disposal	Incineration of waste at an approved USEPA incinerator is recommended.
Hazard(s) not otherwise classified (HNOC)	None known.

3. Composition/information on ingredients

Substances

Chemical name	Common name and synonyms	CAS number	%
PredniSone	cyyc	53-03-2	5mg/5mL
Composition comments	Refer to Physician's Desk Reference for comr	non components present at	<1%
4. First-aid measures			
Inhalation	Get medical attention if symptoms occur.		
Skin contact	Wash off with soap and water. Get medical at	tention if irritation develops	and persists.
Eye contact	Rinse with water. Get medical attention if irrita	ation develops and persists.	
Ingestion	Rinse mouth. Get medical attention if symptor call a poison control center immediately.	ns occur. If ingestion of a la	rge amount does occur,
Most important symptoms/effects, acute and delayed	The following side effects have been reported hypersensitivity reactions, cardiovascular, enc		

PredniSONE Oral Solution USP, 5mg/5mL

Indication of immediate medical attention and special treatment needed General information Provide general supportive measures and treat symptomatically.

Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

5. Fire-fighting measures

Suitable extinguishing media	Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).
Unsuitable extinguishing media	Do not use water jet as an extinguisher, as this will spread the fire.
Specific hazards arising from the chemical	During fire, gases hazardous to health may be formed.
Special protective equipment and precautions for firefighters	Self-contained breathing apparatus and full protective clothing must be worn in case of fire.
Fire fighting equipment/instructions	Use water spray to cool unopened containers.
Specific methods	Use standard firefighting procedures and consider the hazards of other involved materials.
General fire hazards	No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures	Keep unnecessary personnel away. Wear appropriate personal protective equipment (See Section 8).
Methods and materials for containment and cleaning up	Wipe up with absorbent material. Following product recovery, flush area with water. Incineration of waste at an approved USEPA incinerator is recommended.
Environmental precautions	Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handlingAvoid contact with eyes, skin, and clothing. Wash hands thoroughly after handling.Conditions for safe storage,
including any incompatibilitiesStore at 25°C (77°F); excursions permitted to 15 - 30 °C (59 - 86 °F). Keep container tightly closed.
Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls/personal protection

Occupational exposure limits	No exposure limits noted for ingredient(s).
Biological limit values	No biological exposure limits noted for the ingredient(s).
Appropriate engineering controls	Ventilation should be matched to conditions.
Individual protection measures	, such as personal protective equipment
Eye/face protection	None required for consumer use. In laboratory, medical or industrial settings, safety glasses with side shields are recommended. The use of goggles or full face protection may be required depending on the industrial exposure setting. Contact a health and safety professional for specific information.
Skin protection	
Hand protection	For consumer use, no unusual precautions are necessary.
Other	None required for consumer use. In laboratory, medical or industrial settings, gloves and lab coats are recommended. The use of additional personal protective equipment such as shoe coverings, gauntlets, hood or head coverings may be necessary. Contact a health and safety professional for specific information.
Respiratory protection	None required for consumer use. Respirators may be required for certain laboratory and manufacturing tasks if engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (where exposure limits have not been established). Workplace risk assessments should be completed before specifying and implementing respirator usage. All respirators must conform to specifications for efficiency and performance. In the United States of America, if respirators are used, a program should be instituted to assure compliance with OSHA Standard 29 CFR 1910.134. Respirator type: Air-purifying respirator with an appropriate, air-purifying filter, cartridge or canister. Contact a health and safety professional or manufacturer for specific information.
Thermal hazards	Wear appropriate thermal protective clothing, when necessary.

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

9. Physical and chemical properties

Appearance	
Physical state	Liquid.
Form	Liquid.
Color	Colorless, clear.
Odor	Not available.
Odor threshold	Not available.
рН	Not available.
Melting point/freezing point	Not available.
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.
Upper/lower flammability or exp	losive limits
Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Explosive limit - lower (%)	Not available.
Explosive limit - upper (%)	Not available.
Vapor pressure	Not available.
Vapor density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Slightly soluble
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
10. Stability and reactivity	
Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
Conditions to avoid	Contact with incompatible materials. Exposure to light.
Incompatible materials	Strong oxidizing agents.

Hazardous decomposition No hazardous decomposition products are known. products

11. Toxicological information

Information on likely routes of exposure

Inhalation	Not expected to be hazardous in final pharmaceutical form.
Skin contact	Not expected to be hazardous in final pharmaceutical form.
Eye contact	Not expected to be hazardous in final pharmaceutical form. Contact with eyes may cause temporary irritation.
Ingestion	Ingestion may cause irritation and stomach discomfort. Anaphylactoid or hypersensitivity reactions may occur.

PredniSONE Oral Solution USP, 5mg/5mL

Symptoms related to the physical, chemical and toxicological characteristics	The following side effects have been reported with corticosteroids: Anaphylactoid or hypersensitivity reactions, cardiovascular, endocrine, and gastrointestinal systems reactions.
Information on toxicological effe	ects
Acute toxicity	May be harmful if swallowed in large quantities.
Skin corrosion/irritation	Prolonged skin contact may cause temporary irritation.
Serious eye damage/eye irritation	May cause temporary eye irritation.
Respiratory or skin sensitizatior	1
Respiratory sensitization	Not a respiratory sensitizer.
Skin sensitization	Anaphylactoid or hypersensitivity reactions may occur.
Germ cell mutagenicity	This product is not expected to be mutagenic.
Carcinogenicity	Long-term studies in animals have not been conducted to evaluate carcinogenic potential
IARC Monographs. Overall I	Evaluation of Carcinogenicity
	 3 Not classifiable as to carcinogenicity to humans. d Substances (29 CFR 1910.1001-1050)
OSHA Specifically Regulate Not listed.	d Substances (29 CFR 1910.1001-1050)
OSHA Specifically Regulate	
OSHA Specifically Regulate Not listed.	d Substances (29 CFR 1910.1001-1050) Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Drug is present in breast milk. A decision should be made whether to discontinue the drug, taking
OSHA Specifically Regulate Not listed. Reproductive toxicity Specific target organ toxicity -	d Substances (29 CFR 1910.1001-1050) Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Drug is present in breast milk. A decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother.
OSHA Specifically Regulate Not listed. Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity -	d Substances (29 CFR 1910.1001-1050) Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Drug is present in breast milk. A decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother. Not classified.
OSHA Specifically Regulate Not listed. Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity - repeated exposure	d Substances (29 CFR 1910.1001-1050) Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Drug is present in breast milk. A decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother. Not classified. Not classified.
OSHA Specifically Regulate Not listed. Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity - repeated exposure Aspiration hazard	 d Substances (29 CFR 1910.1001-1050) Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Drug is present in breast milk. A decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother. Not classified. Not classified. Not classified. See package insert.
OSHA Specifically Regulate Not listed. Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity - repeated exposure Aspiration hazard Further information	 d Substances (29 CFR 1910.1001-1050) Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Drug is present in breast milk. A decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother. Not classified. Not classified. Not classified. See package insert.

Ecotoxicity	The product is not classified as environmentally hazardou
Persistence and degradability	No data is available on the degradability of this product.
Bioaccumulative potential	No data available.
Mobility in soil	Expected to be mobile in soil.

None.

13. Disposal considerations

Other adverse effects

•	
Disposal instructions	Collect and reclaim or dispose in sealed containers at licensed waste disposal site.
Local disposal regulations	Dispose in accordance with all applicable regulations.
Hazardous waste code	The waste code should be assigned in discussion between the user, the producer and the waste disposal company.
Waste from residues / unused products	Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).
Contaminated packaging	Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

14. Transport information

DOT

Not regulated as dangerous goods.

ΙΑΤΑ

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Not applicable. Annex II of MARPOL 73/78 and the IBC Code

15. Regulatory information

15. Regulatory information	n	
US federal regulations	This material is not listed on the US TSCA Inventory. Therefore, it ca exempt purposes such as R&D or drug use.	an only be used for TSCA
	Over-the-counter drugs in their solid final form (i.e. tablets or pills) ar the criteria of the Federal OSHA Hazard Communication Standard 2 in an industrial setting where a component's occupational exposure can be considered hazardous.	9 CFR 1910.1200. However,
	OSHA GHS: GHS symbols in consumer packaged form are not requ 1910.1200(b)(5) and OSHA 29 CFR 1910.1200(b)(5)(iii).	ired per OSHA 29 CFR
TSCA Section 12(b) Export	Notification (40 CFR 707, Subpt. D)	
Not regulated. OSHA Specifically Regulate Not listed.	d Substances (29 CFR 1910.1001-1050)	
CERCLA Hazardous Substa Not listed.	nce List (40 CFR 302.4)	
Superfund Amendments and Re	authorization Act of 1986 (SARA)	
Hazard categories	Immediate Hazard - No Delayed Hazard - No Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No	
SARA 302 Extremely hazard Not listed.	dous substance	
SARA 311/312 Hazardous chemical	No	
SARA 313 (TRI reporting) Not regulated.		
Other federal regulations		
Clean Air Act (CAA) Sectior	112 Hazardous Air Pollutants (HAPs) List	
Not regulated. Clean Air Act (CAA) Sectior	112(r) Accidental Release Prevention (40 CFR 68.130)	
Not regulated.		
Safe Drinking Water Act (SDWA)	Not regulated.	
US state regulations		
US. Massachusetts RTK - S	ubstance List	
Not regulated. US. New Jersey Worker and	Community Right-to-Know Act	
Not listed.		
US. Pennsylvania Worker a PredniSone (CAS 53-03-	nd Community Right-to-Know Law 2)	
US. Rhode Island RTK		
Not regulated.		
	5 Water and Toxic Enforcement Act of 1986 (Proposition 65): This materi isted as carcinogens or reproductive toxins.	ial is not known to contain
International Inventories		
Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	Yes
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	Yes
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	Yes

Country(s) or region	Inventory name	On inventory (yes/no)*
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	Yes
Korea	Existing Chemicals List (ECL)	Yes
New Zealand	New Zealand Inventory	Yes
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	Yes
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	Yes

*A "Yes" indicates this product complies with the inventory requirements administered by the governing country(s). A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

-	•
Issue date	25-April-2015
Revision date	-
Version #	01
References	 PredniSone Oral Solution USP, 5mg/5 mL, Package Insert, West-Ward Pharmaceuticals Corporation Columbus, Ohio
	2) PDR – Physicians Desk Reference.
	3) Ariel Webinsight. Regulatory and ChemExpert Database.
Disclaimer	West-Ward Pharmaceuticals Corporation cannot anticipate all conditions under which this information and its product, or the products of other manufacturers in combination with its product, may be used. It is the user's responsibility to ensure safe conditions for handling, storage and disposal of the product, and to assume liability for loss, injury, damage or expense due to improper use. The information in the sheet was written based on the best knowledge and experience currently available.